{
    "clinical_study": {
        "@rank": "43643", 
        "arm_group": {
            "arm_group_label": "psychiatric patients treated with QT-prolonging drugs"
        }, 
        "brief_summary": {
            "textblock": "Observational study in 7 psychiatric hospitals in Flanders. Patients are included when a\n      QT-prolonging drug is added to a medication profile that already contains a potential\n      QT-prolonging drug. An ECG is taken before the administration of the new drug and a week\n      after starting the new drug to investigate the change in duration of the QTc-interval. Risk\n      factors for developing QT-prolongation and blood concentrations of potassium and creatinine\n      are documented."
        }, 
        "brief_title": "QT-prolongation in Psychiatric Hospitals", 
        "condition": "QT-prolongation", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  inpatient in one of the 7 participating psychiatric hospitals\n\n          -  QT-prolonging drug in the medication profile and the doctor prescribes another\n             QT-prolonging drug\n\n        Exclusion Criteria:\n\n          -  age < 18 year"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "Observational study in 7 psychiatric hospitals in Flanders. Patients are included when a\n        QT-prolonging drug is added to a medication profile that already contains a potential\n        QT-prolonging drug."
            }
        }, 
        "enrollment": {
            "#text": "300", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 21, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02043925", 
            "org_study_id": "VF/2010/02"
        }, 
        "intervention": {
            "arm_group_label": "psychiatric patients treated with QT-prolonging drugs", 
            "description": "all the drugs that are mentioned in the lists of QT-prolonging drugs of CredibleMeds (www.crediblemeds.org)", 
            "intervention_name": "drugs linked with QT-prolongation", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "QT-prolongation", 
            "Torsade de Pointes", 
            "drug interactions", 
            "psychiatry"
        ], 
        "lastchanged_date": "February 19, 2014", 
        "location": {
            "contact": {
                "email": "eline.vandael@pharm.kuleuven.be", 
                "last_name": "Eline Vandael, PhD-student", 
                "phone": "+32 16 379583"
            }, 
            "facility": {
                "address": {
                    "city": "Eeklo", 
                    "country": "Belgium"
                }, 
                "name": "Psychiatrisch Centrum Sint-Jan"
            }, 
            "investigator": {
                "last_name": "Johan Reyntens", 
                "role": "Sub-Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Belgium"
        }, 
        "number_of_groups": "1", 
        "official_title": "QT-prolongation in Psychiatric Hospitals", 
        "overall_contact": {
            "email": "eline.vandael@pharm.kuleuven.be", 
            "last_name": "Eline Vandael, PhD-student", 
            "phone": "+32 16 379583"
        }, 
        "overall_contact_backup": {
            "email": "veerle.foulon@pharm.kuleuven.be", 
            "last_name": "Veerle Foulon, Prof."
        }, 
        "overall_official": {
            "affiliation": "Katholieke Universiteit Leuven", 
            "last_name": "Eline Vandael, PhD-student", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Belgium: Ethics Committee", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "change in QTc-interval (corrected for heart rate)", 
            "safety_issue": "Yes", 
            "time_frame": "before and one week after the start of a QT-prolonging drug"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02043925"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Katholieke Universiteit Leuven", 
            "investigator_full_name": "Eline Vandael", 
            "investigator_title": "PhD-student", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "Katholieke Universiteit Leuven", 
        "sponsors": {
            "collaborator": {
                "agency": "Agentschap voor Innovatie door Wetenschap en Technologie", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Katholieke Universiteit Leuven", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2010", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "February 2014"
    }
}